Thanks Simon for taking the time to update the Rosetta@home ad. Also good to
know that you still support our Rosetta activities.
Here
is a screen shot of the home page showing the new ad
in case anyone wants to see it in
context. I also
wanted to say that I think the new design and functionallity of Betterhumans
(news feed comments, tags...) is a big improvement.
I really appreciate your efforts
to improve and develop this site and community, Simon. I think a lot of us
do but I guess it takes some getting used to the new 'look and feel' of the site which may
be why there hasn't been as much feedback and comments as one might expect.
I also wanted to provide a link to the recent
NPR radio story
(audio and text)
about Rosetta@home which includes soundbites by Rosetta@home lead scientist
David Baker and by David Kim - the other David at Rosetta and the person who
actually created Rosetta@home by integrating the Rosetta protein modelling software
with the open source BOINC distributed computing package. The story seems to
contain one factual error, though: the commentator claims that more than
100,000 have signed up for Rosetta@home, where according to boincstats,
there are
currently just 33,000 active participants (returned work in the last
month) with 56,000 active computers. This compares to 200,000 active
computers
participating in folding@home and about 270,000 crunching for
seti@home. I really believe that Rosetta's very promising disease
related research deserves at least as much computing power as these
other projects...
After the recent Gates foundation donation to HVI research (some of that
money goes to David Baker's lab) there were concerns that Rosetta@home would
now predominantly direct its research towards HIV and neglect other areas.
I therefore wanted to quote the following statement by David Baker from the
Rosetta@home forum:
The methods we are using to design potential HIV vaccines should be directly
transferable to design of vaccines to other pathogens--basically, we design
proteins that mimic critical regions on the pathogen to stimulate the immune
system to make antibodies against these parts of the virus, bacteria, etc.
While we are very excited about making a serious push towards an HIV vaccine,
this will not reduce our efforts to develop new proteins to target genes
causing cancer. In fact, Jim Havranak in my group has just had very exciting
results on engineering an endonuclease to cut within a human disease gene.